DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Clofibrate
Clofibrate
Partial Agreement in the Social and Public Health Field
Clofibrate Causes an Upregulation of PPAR- Target Genes but Does Not
Pharmaceuticals Appendix
Colesevelam Hydrochloride (Cholestagel) a New, Potent Bile Acid Sequestrant Associated with a Low Incidence of Gastrointestinal Side Effects
Download Product Insert (PDF)
Rosuvastatin
Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: the Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
NCEP Drug Treatment
Lipid Lowering Drugs Prescription and the Risk of Peripheral Neuropathy
Articles Article: Non-Statin Treatments for Managing LDL Cholesterol and Their Outcomes Download
Increased Cholesterol Epoxide Hydrolase Activity in Clofibrate-Fed Animals
2 12/ 35 74Al
Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
Clofibrate Report1 from the Committee of Principal Investigators
Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
Stembook 2018.Pdf
Front Matter (PDF)
COLESTID® Colestipol Hydrochloride 5 G Granules for Oral Suspension
Top View
Lipotropics, Other
Research Article Treatment with PPAR Agonist Clofibrate Inhibits the Transcription and Activation of Srebps and Reduces Tr
Ciprofibrate 100Mg Tablets
Peroxisome Proliferator-Activated Receptors (Ppars): Novel Therapeutic Targets in Renal Disease
(PPAR) Agonists in Substance Use Disorders: a Synthesis of Preclinical and Human Evidence
Pparα Ligand Clofibrate Ameliorates Blood Pressure and Vascular Reactivity in Spontaneously Hypertensive Rats
Changes Highlighted Final Version Date of Issue
Lipid Management in Patients with Endocrine Disorders: an Endocrine
Peroxisome Proliferator–Activated Receptor- Regulates Fatty Acid Utilization in Primary Human Skeletal Muscle Cells
Lipofen® (Fenofibrate Capsules USP) for Oral Use 50 Mg and 150 Mg
Etofibrate but Not Controlled-Release Niacin Decreases LDL Cholesterol and Lipoprotein (A) in Type Iib Dyslipidemic Subjects
Cholesterol Lowering Medications
Accessibility Improving Information Using Online Patient Drug Reviews
Combined Use of a Fibrate and Orlistat for the Treatment of Obesity
Comparative Study on the in Vivo and in Vitro Antilipolytic Effects of Etofibrate, Nicotinic Acid and Clofibrate in the Rat
Combined Effects of Probucol and Bezafibrate on Lipoprotein Metabolism and Liver Cholesteryl Ester Transfer Protein Mrna in Chol
Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value
Lipotropics, Other Therapeutic Class Review (TCR)
Study Protocol 1002-038 Final, 11 November 2016
Guidelines for ATC Classification and DDD Assignment 2021
Despite Affordability, Low Utilization of Lipid Lowering Drugs in Iran: Trend Analysis and Benchmarking 2005-2016
Highlights of Prescribing Information
LIPID-LOWERING AGENTS (Anti- Or Hypo-Lipidemic Drugs)
Pharmaceutical Appendix to the Tariff Schedule 2
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Gemfibrozil Tablets, USP
Guidelines for ATC Classification and DDD Assignment 2013
Hypolipidemic Drug by Janardan K
Final Evidence Report
Application of WHO ATC/ DDD Methods in Medicine Utilisation Research: a Hands-On Experience Ilse Truter 2019
TRICOR (Fenofibrate) Tablet, for Oral Use • TRICOR Can Increase Serum Transaminases
Study Protocol 1002FDC-053 Amendment 1, 18 October 2017
Apolipoprotein a and B (Sf 100-400) Metabolism During Bezafibrate Therapy in Hypertriglyceridemic Subjects
1246 Cardiovascular Drugs
Effect of Bezafibrate on Office, Home and Ambulatory Blood Pressure In